00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
23:17 , Jan 17, 2019 |  BC Extra  |  Company News

Management tracks: eGenesis names Sekhri CEO

Xenotransplantation company eGenesis Inc. (Cambridge, Mass.) hired Paul Sekhri as president and CEO. He succeeds interim CEO Julie Sunderland, who will become a director. Sekhri was president and CEO of Lycera Corp. (Ann Arbor, Mich.)...
20:12 , Jun 15, 2018 |  BC Extra  |  Company News

Management tracks: JHL, Aclaris, CytomX

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) hired Ellis Chu as CFO. He was managing director and head of greater China at Ion Pacific Ltd., an Asia-focused venture capital merchant bank. Dermatology company Aclaris Therapeutics...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
22:28 , Jan 18, 2018 |  BC Extra  |  Company News

Management tracks: Aslan, FIT Biotech

Cancer company Aslan Pharmaceuticals Ltd. (TPEx:6497) hired Stephen Doyle as head of China, effective February. He was VP and head of specialty care for China at Boehringer Ingelheim GmbH (Ingelheim, Germany). Antibody gene delivery company...
20:31 , Feb 3, 2017 |  BioCentury  |  Strategy

Delineating IL-2

While Celgene Corp. has a history of entering creative deals that enable its smaller partners to retain control over early development, Delinia Inc. ’s clinically validated approach to treating autoimmune diseases, paired with preclinical proof-of-concept...
19:48 , Jan 13, 2017 |  BC Week In Review  |  Company News

Anokion, Celgene deal

Celgene's Celgene Switzerland LLC affiliate and Anokion partnered to use Anokion's immune tolerizing platform to develop therapies for autoimmune diseases. Anokion will receive $45 million up front, which includes an undisclosed equity stake and non-dilutive...
00:02 , Jan 10, 2017 |  BC Extra  |  Company News

Celgene partners with Anokion, lifts 2017 guidance

Celgene Corp. (NASDAQ:CELG) and Anokion S.A. (Ecublens, Switzerland) partnered to use the Swiss biotech's immune tolerizing platform to develop therapies for autoimmune diseases. Celgene made an equity investment in Anokion and obtained an option to...
07:00 , Aug 11, 2016 |  BC Innovations  |  Product R&D

Selecta spreads tolerance

Having been founded in 2008 to use its nanoparticles to stoke the immune system for vaccine applications, Selecta Biosciences Inc. is extending the platform with a 180˚ turn on that principle, using the same particles...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Conjugation of glycophorin A (GYPA)-binding peptides to protein drugs to reduce anti-drug immunity

Drug delivery TECHNOLOGY: Targeting domains A GYPA-binding peptide that targets therapeutic proteins to erythrocytes could help prevent immune responses to the drugs. In normal mice, injection of asparaginase conjugated to a peptide that binds GYPA...